论文部分内容阅读
对９名男性健康自愿受试者单剂随机三交叉口服试验洛美沙星片和胶囊及参比胶囊４００ｍｇ后的药代动力学参数和相对生物利用度进行了比较。血、尿药浓度用ＨＰＬＣ柱切换样本直接进样法进行检测，按统计矩进行药代动力学分析。实验结果表明：口服试验洛美沙星片和胶囊及参比胶囊后，其ＡＵＣ分别为３２５１±４５４、３３３７±５９２与３４１０±６１３ｍｇ／Ｌ·ｈ，Ｃｍａｘ：３４４±０４５、３４１±０３８、３４６±０３９与３４４±０４５ｍｇ／Ｌ，Ｔｍａｘ：１２８±０３６、１０９±０３３与１１１±０３９ｈ。给药后４８ｈ后分别可由尿中排出给药量的６９６０％、６８００％与６８５３％。相对生物利用度分别为９６２７％和９８３８％。
Pharmacokinetic parameters and relative bioavailability of lomefloxacin tablets and capsules and reference capsules after single dose randomized crossover study in nine male volunteers were compared. Blood, Urine drug concentration by HPLC column switching sample direct injection method for testing, according to the statistical moments for pharmacokinetic analysis. The experimental results showed that after oral administration of lomefloxacin tablets and capsules and reference capsules, the AUC were 3251 ± 454, 3337 ± 592 and 3410 ± 613 mg / L · h, respectively, Cmax: 344 ± 045, 341 ± 038, 346 ± 039 and 344 ± 045mg / L, Tmax: 128 ± 036, 109 ± 033 and 111 ± 039h. After administration of 48h, respectively, the urinary excretion of 69.60%, 6800% and 6853%. The relative bioavailability was 9627% and 9838% respectively.